Global API Leader Jubilant Life Sciences operates six USFDA approved manufacturing facilities across India, USA, and Canada, indicating strong potential for contract manufacturing, scale-up partnerships, and API supply opportunities across North America and beyond.

Integrated Life Sciences With activities spanning Pharmaceuticals, Life Science Ingredients, and Drug Discovery Solutions, there are cross-sell opportunities to provide end-to-end solutions from raw materials and intermediates to discovery services and branded products in over 100 countries.

Remdesivir Heritage Historically involved in remdesivir development and launches in India, Jubilant has established capabilities in high-demand antiviral products, suggesting potential for ongoing collaborations in infectious disease therapeutics and injectable/subjoints.

Expansion Assets Acquisitions such as pyridine production assets from Solvay and ongoing asset investments indicate readiness to scale manufacturing capacity and supply chain resiliency, presenting opportunities for strategic manufacturing partnerships and long-term supply agreements.

Global Footprint A workforce of thousands and a reach across 100+ countries, plus a network of radiopharmacies in the US, points to opportunities for distribution partnerships, regulatory-friendly market entry, and co-marketing of specialty intermediates and radiopharmaceuticals.